7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors

Journal of Medicinal Chemistry

Volumn 51, Issue 13, 2008, Pages 3777-3787

  Frey, Robin R ^a   Curtin, Michael L ^a   Albert, Daniel H ^a   Glaser, Keith B ^a   Pease, Lori J ^a   Soni, Niru B ^a   Bouska, Jennifer J ^a   Reuter, David ^a   Stewart, Kent D ^a   Marcotte, Patrick ^a   Bukofzer, Gail ^a   Li, Junling ^a   Davidsen, Steven K ^a   Michaelides, Michael R ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 [5 AMINO 3 (1 METHYL 1H PYRAZOL 4 YL)PYRAZOLO[1,5 A]PYRIMIDIN 6 YL]PHENYL] 3 (3 TRIFLUOROMETHYLPHENYL)UREA; ESTRADIOL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLO[1,5 A]PYRIMIDINE DERIVATIVE; SERIC GONADOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; EDEMA; ENZYME INHIBITION; FEMALE; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; UTERUS DISEASE;

ANIMALS; EDEMA; FEMALE; MALE; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; UREA; UTERINE DISEASES;

EID: 46849112796     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701397k     Document Type: Article

References (42)

1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The Protein Kinase Complement of the Human Genome. Science 2002, 298, 1912-1934.
2. Blume-Jensen, P.; Hunter, T. Oncogenic Kinase Signalling. Nature 2001, 411, 355-365.
3. Holmgren, L.; O'Reilly. M. S.; Folkman, J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1995, 1, 149-153.
4. Fukumura, D.; Xu, L.; Chen, Y.; Gohongi, T.; Seed, B.; Jain, R. K. Hypoxia and Acidosis Independently Up-Regulate Vascular Endothelial Growth Factor Transcription in Brain Tumors in Vivo. Cancer Res. 2001, 61, 6020-6024.
5. Dvorak, H. F. Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy. J. Clin. Oncol. 2002, 20, 4368-4380.
6. Carmeliet, P. VEGF as a Key Mediator of Angiogenesis in Cancer. Oncology 2005, 69 (Suppl. 3), 4-10.
7. Beck, L.; D'Amore, P. A. Vascular development: cellular and molecular regulation. FASEB J. 1997, 11, 365-373.
8. Reynolds, L. P.; Killilea, S. D.; Redmer, D. A. Angiogenesis in the female reproductive system. FASEB J. 1992, 6, 886-892.
9. Augustin, H. G. Antiangiogenic tumor therapy: will it work? Trends Pharmacol. Sci. 1998, 19, 216-222.
10. Ferrara, N.; Hillan, K. J.; Gerber, H.-P.; Novotny, W. Discovery and Development of Bevacizumab, an Anti-VEGF Antibody for Treating Cancer. Nat. Rev. Drug Discovery 2004, 5, 391-400.
11. Gschwind, A.; Fischer, O. M.; Ullrich, A. The Discovery of Receptor Tyrosine Kinases: Targets for Cancer Therapy. Nat. Rev. Cancer 2004, 4, 361-370.
12. Board, R.; Jayson, G. C. Platelet-Derived Growth Factor Receptor (PDGFR): A Target for Anticancer Therapeutics. Drug Resist. Updates 2005, 8, 75-83.
13. Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Synthesis and Biological Evaluations of 3-Substituted Molindones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases. J. Med. Chem. 1998, 41, 2588-2603.
14. Laird, A. D.; Vajkoczy, P.; Shawver, L. K.; Thurnher, A.; Liang, C.; Mohammadi, M.; Schlessinger, J.; Ullrich, A.; Hubbard, S. R.; Blake, R. A.; Fong, T. A. T.; Strawn, L. M.; Sun, L.; Tang, C.; Hawtin, R.; Tang, F.; Shenoy, N.; Hirth, K. P.; McMahon, G.; Cherrington, J. M. SU6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors. Cancer Res. 2000, 60, 4152-4160.
15. Fong, T. A. T.; Shawver, L. K.; Sun, L.; Tang, C.; App, H.; Powell, T. J.; Kim, Y. H.; Schreck, R.; Wang, X.; Risau, W.; Ullrich, A.; Hirth, K. P.; McMahon, G. SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk- 1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types. Cancer Res. 1999, 59, 99-106.
16. Sun, L.; Tran, N.; Liang, C.; Hubbard, S.; Tang, F.; Lipson, K.; Schreck, R.; Zhou, Y.; McMahon, G.; Tang, C. Identification of Substituted 3-[(4,5,6,7-Tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as Growth Factor Receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rβ Tyrosine Kinases. J. Med. Chem. 2000, 43, 2655-2663.
17. Klebl, B. M.; Müller, G. Second-generation kinase inhibitors. Expert Opin. Ther. Targets 2005, 9, 975-993.
18. Hicklin, D. J.; Ellis, L. M. Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis. J. Clin. Oncol. 2005, 23, 1011-1027.
19. Casanovas, O.; Hicklin, D. J.; Bergers, G.; Hanahan, D. Drug Resistance by Evasion of Antiangiogenic Targeting of VEGF Signaling in Late-Stage Pancreatic Islet Tumors. Cancer Cell 2005, 8, 299-309.
20. Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J. Y.; Chu, J.-Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T. C.; Tang, F.; Wei, J.; Tang, C. Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol- (3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-Dimethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase. J. Med. Chem. 2003, 46, 1116-1119.
21. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Res. 2004, 64, 7099-7109.
22. Dai, Y.; Guo, Y.; Frey, R. R.; Ji, Z.; Curtin, M. L.; Ahmed, A. A.; Albert, D. H.; Arnold, L.; Arries, S. S.; Bariozzari, T.; Bauch, J. L.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Guo, J.; Li, J.; Marcotte, P. A.; Marsh, K. C.; Moskey, M. D.; Pease, L. J.; Stewart, K. D.; Stoll, V. S.; Tapang, P.; Wishart, N.; Davidsen, S. K.; Michaelides, M. R. Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors. J. Med. Chem. 2005, 48, 6066-6083.
23. Curtin, M. L.; Frey, R. R.; Heyman, H. R.; Sards, K. A.; Steinman, D. H.; Holms, J. H.; Bousquet, P. F.; Cunha, G. A.; Moskey, M. D.; Ahmed, A. A.; Pease, L. J.; Glaser, K. B.; Stewart, K. D.; Davidsen, S. K.; Michaelides, M. R. Isoindolinone Ureas: A Novel Class of KDR Kinase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 4505-4509.
24. (a) Albert, D. H.; Tapang, P.; Magoc, T. J.; Pease, L. J.; Reuter, D. R.; Wer, R.-Q.; Li, J.; Guo, J.; Bousquet, P. F.; Ghoreishi-Haack, N. S.; Wang, B.; Bukofzer, G. T.; Wang, Y.-C.; Stavropoulos, J. A.; Hartandi, K.; Niquette, A. L.; Soni, N.; Johnson, E. F.; McCall, J. O.; Bouska, J. J.; Luo, Y.; Donawho, C. K.; Dai, Y.; Marcotte, P. A.; Glaser, K. B.; Michaelides, M. R.; Davidsen, S. K. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 2006, 5, 995-1006.
25. (b) Dai, Y.; Hartandi, K.; Ji, Z.; Ahmed, A. A.; Albert, D. H.; Bauch, J. L.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Harris, C. M.; Hickman, D.; Guo, J.; Li, J.; Marcotte, P. A.; Marsh, K. C.; Moskey, M. D.; Martin, R. L.; Olson, A. M.; Osterling, D. J.; Pease, L. J.; Soni, N. B.; Stewart, K. D.; Stoll, V. S.; Tapang, P.; Reuter, D. R.; Davidsen, S. K.; Michaelides, M. R. Discovery of N-(4-(3-Amino-1H-indazol-4-yl) phenyl)-N′-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitor. J. Med. Chem. 2007, 50, 1584-1597.
26. The development of RTK inhibitors in the clinic has been extensively reviewed. For recent reviews, see the following: (a) Arora, A.; Scholar, E. M. Role of Tyrosine Kinase Inhibitors in Cancer Therapy. J. Pharmacol. Exp. Ther. 2005, 315, 971-979.
27. (b) Laird, A. D.; Cherrington, J. M. Small Molecule Tyrosine Kinase Inhibitors: Clinical Development of Anticancer Agents. Expert Opin. Invest. Drugs 2003, 12, 51-64.
28. (c) Manley, P. W.; Bold, G.; Brüggen, J.; Fendrich, G.; Furet, P.; Mestan, J.; Schnell, C.; Stolz, B.; Meyer, T.; Meyhack, B.; Stark, W.; Strauss, A.; Wood, J. Advances in the Structural Biology, Design and Clinical Development of VEGF-R Kinase Inhibitors for the Treatment of Angiogenesis. Biochim. Biophys. Acta 2004, 1697, 17-27.
29. Traxler, P.; Furet, P. Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors. Pharmacol. Ther. 1999, 82, 195-206.
30. Bold, G.; Florsheimer, A.; Furet, P.; Imbach, P.; Masuya, K.; Schoepfer, R. Scientists at Novartis have independently discovered 7-amino-pyrazolo[ 1,5-a]pyrimidine ureas as kinase inhibitors: Organic compounds, US2005/0222171 A1, 2005.
31. Alcade, E.; deMendoza, J.; Garcia-Marquina, J. M.; Almera, C.; Elguero, J. Etude de la Réaction du β-Aminocrotonitrile et du α-Formyl Phénylacétonitrile avec l'Hydrazine: Synthèse d'Amino-7-pyrazolo[1,5-a]pyrimidines. J. Heterocycl. Chem. 1974, 11, 423-429.
32. Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. Chem. Rev. 1995, 95, 2457-2483.
33. Fraley, M. E.; Hoffman, W. F.; Rubino, R. S.; Hungate, R. W.; Tebben, A. J.; Rutledge, R. Z.; McFall, R. C.; Huckle, W. R.; Kendall, R. L.; Coll, K. E.; Thomas, K. A. Synthesis and Initial SAR Studies of 3,6-Disubstituted Pyrazolo[1,5-a]pyrimidines: A New Class of KDR Kinase Inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 2767-2770.
34. Nam, N. L.; Grandberg, I. I.; Sorokin, V. I. Pyrazolopyrimidines Based on 5-Aminopyrazoles Unsubstituted at the Position 1. Chem. Heterocycl. Compd. 2002, 38, 1371-1374.
35. Gribble, F. M.; Loussouarn, G.; Tucker, S. J.; Zhao, C.; Nichols, C. G.; Ashcroft, F. M. A Novel Method for Measurement of Submembrane ATP Concentration. J. Biol. Chem. 2000, 275, 30046-30049.
36. Miyazaki, Y.; Matsunaga, S.; Tang, J.; Maeda, Y.; Nakano, M.; Philippe, R. J.; Shibahara, M.; Liu, W.; Sato, H.; Wang, L.; Nolte, R. T. Novel 4-Amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 Dual Inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 2203-2207.
37. Fraley, M. E.; Rubino, R. S.; Hoffman, W. F.; Hambaugh, S. R.; Arrington, K. L.; Hungate, R. W.; Bilodeau, M. T.; Tebben, A. J.; Rutledge, R. Z.; Kendall, R. L.; McFall, R. C.; Huckle, W. R.; Coll, K. E.; Thomas, K. A. Optimization of a Pyrazolo[1,5-a]pyrimidine Class of KDR Kinase Inhibitors: Improvements in Physical Properties Enhance Cellular Activity and Pharmacokinetics. Bioorg. Med. Chem. Lett. 2002, 12, 3537-3541.
38. Aronov, A. M.; Baker, C.; Bemis, G. W.; Cao, J.; Chen, G.; Ford, P. J.; Germann, U. A.; Green, J.; Hale, M. R.; Jacobs, M.; Janetka, J. W.; Maltais, F.; Martinez-Botella, G.; Namchuk, M. N.; Straub, J.; Tang, Q.; Xie, X. Flipped Out: Structure-Guided Design of Selective Pyrazolylpyrrole ERK Inhibitors. J. Med. Chem. 2007, 50, 1280-1287.
39. Ma, W.; Tan, J.; Matsumoto, H.; Robert, B.; Abrahamson, D. R.; Das, S. K.; Dey, S. K. Adult Tissue Angiogenesis: Evidence for Negative Regulation by Estrogen in the Uterus. Mol. Endocrinol. 2001, 15, 1983-1992.
40. Inhibition values exceeding 30% were significantly different (p < 0.05) from vehicle-treated controls.
41. 50 < 1000 nM at lower ATP concentration included Src, Lck, JAK2, Abl, and Fyn. Without inhibition data at 1 mM ATP, however, it is not possible to make a direct comparison of these screening data with the data reported in Table 7.
42. Kolb, A. J.; Kaplita, P. V.; Hayes, D. J.; Park, Y.-W.; Pernell, C.; Major, J. S.; Mathis, G. Tyrosine Kinase Assays Adapted to Homogeneous Time-Resolved Fluorescence. Drug Discovery Today 1998, 3, 333-342.